Lantheus Holdings公司宣布，由于生产条件相关问题，美国食品药品监督管理局（FDA）将无法在先前设定的2026年6月29日这一目标日期前，批准其候选药物Lnth-2501的新药申请（NDA）。这一消息意味着该药物的审批进程将面临延迟。
Lantheus Holdings公司宣布，由于生产条件相关问题，美国食品药品监督管理局（FDA）将无法在先前设定的2026年6月29日这一目标日期前，批准其候选药物Lnth-2501的新药申请（NDA）。这一消息意味着该药物的审批进程将面临延迟。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.